Calorie restriction mimetics (CRM), also known as energy restriction mimetics, are a hypothetical class of dietary supplements or drug candidates that would, in principle, mimic the substantial anti-aging effects that calorie restriction (CR) has on many laboratory animals and humans. CR is defined as a reduction in calorie intake of 20% (mild CR) to 50% (severe CR) without incurring malnutrition or a reduction in essential nutrients.[1] An effective CRM would alter the key metabolic pathways involved in the effects of CR itself, leading to preserved youthful health and longer lifespan without the need to reduce food intake. The term was coined by Lane, Ingram, Roth of the National Institute on Aging in a seminal 1998 paper in the Journal of Anti-Aging Medicine, the forerunner of Rejuvenation Research.[2] A number of genes and pathways have been shown to be involved with the actions of CR in model organisms and these represent attractive targets for drug discovery and for developing CRM. However, no effective CRM have been identified to date.[1][3][4]
Candidate compounds include:
- Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a stilbenoid, a type of natural phenol, and a phytoalexin produced naturally by several plants, including grapes, and especially the roots of the Japanese Knotweed, from which it is extracted commercially. Resveratrol was proposed to be a CRM based on a series of early reports which found that it increased the lifespan of yeasts, the worm Caenorhabditis elegans, and fruit flies. Scientists involved in these studies went on to found Sirtris Pharmaceuticals, a company working to develop resveratrol analogs as proprietary drugs. This led many companies to produce and market resveratrol dietary supplements. However, studies by independent scientists have failed to replicate these results[5][6][7] Moreover, in every experiment to date, resveratrol at several doses has failed to extend the lifespan of lean, genetically normal mice[8][9][10] or rats.[11]
- The antidiabetic drug metformin was proposed as a possible CRM after it was found that mice administered the drug exhibit similar gene expression changes as CR mice.[12] It is already clinically approved to treat diabetes, and has been used for this indication for the past 40 years. It enhances the sensitivity of insulin receptors on the surface of muscle and fat cells and activates genes that reduce the production of glucose by the liver, thus reducing the risk of non-enzymatic glycation and other age-related damage; these effects are also seen in CR. Subsequently, metformin was reported to extend the lifespan of short-lived or genetically cancer-prone mouse strains.[13] However, two studies in rats and mice with normal genetics and longevity have found no effect of metformin on maximum lifespan, and only a very small effect on median lifespan.[14][15]
- Oxaloacetate is a metabolic intermediate of the citric acid cycle. In the short-lived roundworm Caenorhabditis elegans, supplementation with oxaloacetate increases the ratio of reduced to oxidized nicotinamide adenine dinucleotide (NAD+:NADH) to activate AMPK and FOXO signaling pathways similar to what occurs in calorie restriction.[16] The increase in the NAD+/NADH ratio is due to the reaction of oxaloacetate to malate in the cytoplasm via the enzyme malate dehydrogenase. In mitochondria that have been isolated out of cells and tested in oxaloacetate-enriched medium, this increase can be quite dramatic.[17] Decreases in the NAD+/NADH ratio has been proposed as a carbohydrate metabolism-controlled cellular senescence mechanism.[18]
- Because of its parallel effects on these pathways, oxaloacetate was proposed as a CR mimetic.[16] In the short-lived roundworm Caenorhabditis elegans, supplementing the medium with oxaloacetate does increase average life expectancy; it was unclear whether it had an effect on maximum lifespan.[16][19] However, when tested by two independent groups of scientists across four university laboratories, oxaloacetate supplements had no effect on lifespan in healthy laboratory mice.[10][20]
- Rimonabant (Acomplia) is an anti-obesity drug initially approved for use in the European Union but later withdrawn due to psychiatric side effects including anxiety and depression.[21] Rimonabant was never approved by the FDA for use in the United States.[22] This is an endocannabinoid-1 receptor blocker. Endocannabinoids are cannabis-like chemicals that stimulate appetite and also regulate energy balance. Overstimulation of the endocannabinoid receptor in the hypothalamus promotes appetite and stimulates lipogenesis. It also blocks the beneficial actions of adiponectin. Rimonabant inhibits these and so it reduces appetite, balances energy, and increases adiponectin, which reduces intra-abdominal fat. It improves lipid profile, glucose tolerance, and waist measurement, and is therefore comparable in effect to calorie restriction (CR).
- Lipoic Acid (α-Lipoic Acid, Alpha Lipoic Acid, or ALA) has failed to extend lifespan in normal mice or rats in numerous studies, either alone[23][24] or as part of combination therapy.[25][26]
- 2-deoxy-D-glucose, or 2DG. 2-Deoxyglucose was the first agent pursued as a possible CRM.[2][4][27] This compound inhibits glycolysis, and can mimic some of the physiological effects of CR, in particular increased insulin sensitivity, reduced glucose levels, reduced body temperature, and other biochemical changes.[2][27] It was reported to extend the lives of C. elegans worms;[28] however, studies in different strains of rats found that 2DG did not extend lifespan at several tested doses, and exhibited toxic effects[27] "Histopathological analysis of the hearts revealed increasing vacuolarization of cardiac myocytes with dose, and tissue staining revealed the vacuoles were free of both glycogen and lipid."[27]
- It has been suggested that rapamycin, a drug that inhibits the mechanistic Target Of Rapamycin (mTOR) pathway, might be a CR mimetic.[4][29] based on the responsiveness of mTORC1 activity to nutrient availability; the fact that mTOR activity is inhibited by CR; the fact that genetically inhibiting mTOR signaling extends maximum lifespan in invertebrate animals, and pharmacologically inhibiting mTOR with rapamycin extends maximum lifespan in both invertebrates and mice.[9][29][30] While knocking out elements of the mTOR cascade seems to block the lifespan effects of rapamycin in invertebrate animals,[29] surprisingly the effects of CR and rapamycin on metabolism and gene expression exhibit substantial differences in mice,[31][32][33] with evidence suggesting that the mechanisms of the two anti-aging therapies may be in large part distinct and possibly additive.[32][33]
Other candidate CRM are:
Lane MA; Ingram DK; Roth GS (Winter 1998). "2-Deoxy-D-glucose feeding in rats mimics physiologic effects of calorie restriction". J Anti-Aging Med. 1 (4): 327–37. doi:10.1089/rej.1.1998.1.327.
Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R (August 2008). "Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span". Cell Metab. 8 (2): 157–68. doi:10.1016/j.cmet.2008.06.011. PMC 2538685. PMID 18599363.
Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R (February 2011). "Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice". J. Gerontol. A Biol. Sci. Med. Sci. 66 (2): 191–201. doi:10.1093/gerona/glq178. PMC 3021372. PMID 20974732.
da Luz, PL; Tanaka L; Brum PC; Dourado PM; Favarato D; Krieger JE; Laurindo FR (September 2012). "Red wine and equivalent oral pharmacological doses of Resveratrol delay vascular aging but do not extend life span in rats". Atherosclerosis. 224 (1): 136–42. doi:10.1016/j.atherosclerosis.2012.06.007. PMID 22818625.
Arkad'eva, A.V.; Mamonov, A.A.; Popovich, I.G.; Anisimov, V.N.; Mikhel'son, V.M.; Spivak, I.M. (2011). "Metformin slows down ageing processes at the cellular level in SHR mice". Tsitologiia. 53 (2): 166–74. PMID 21516824.
Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, Gomes AP, Ward TM, Minor RK, Blouin MJ, Schwab M, Pollak M, Zhang Y, Yu Y, Becker KG, Bohr VA, Ingram DK, Sinclair DA, Wolf NS, Spindler SR, Bernier M, de Cabo R (Jul 31, 2013). "Metformin improves healthspan and lifespan in mice". Nature Communications. 4: 2192. Bibcode:2013NatCo...4.2192M. doi:10.1038/ncomms3192. PMC 3736576. PMID 23900241.
Lee CK, Pugh TD, Klopp RG, Edwards J, Allison DB, Weindruch R, Prolla TA (Apr 15, 2004). "The impact of alpha-lipoic acid, coenzyme Q10 and caloric restriction on life span and gene expression patterns in mice". Free Radic Biol Med. 36 (8): 1043–57. doi:10.1016/j.freeradbiomed.2004.01.015. PMID 15059645.
Minor RK, Smith DL, Sossong AM, Kaushik S, Poosala S, Spangler EL, Roth GS, Lane M, Allison DB, de Cabo R, Ingram DK, Mattison JA (Mar 15, 2010). "Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and increases mortality in rats". Toxicol Appl Pharmacol. 243 (3): 332–9. doi:10.1016/j.taap.2009.11.025. PMC 2830378. PMID 20026095.
Weimer S, Priebs J, Kuhlow D, Groth M, Priebe S, Mansfeld J, Merry TL, Dubuis S, Laube B, Pfeiffer AF, Schulz TJ, Guthke R, Platzer M, Zamboni N, Zarse K, Ristow M (2014). "D-Glucosamine supplementation extends life span of nematodes and of ageing mice". Nature Communications. 5: 3563. Bibcode:2014NatCo...5.3563W. doi:10.1038/ncomms4563. PMC 3988823. PMID 24714520.